Laurus Labs Ltd. (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01010) Laurus Labs Limited, a leading research and development driven pharmaceutical company has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.
And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir / Lamivudine / Efavirenz 300 / 300 / 400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).
This approval enables Laurus Labs to participate directly in GF and also In-Country tenders based on GF funding across Sub-Saharan African region along with our other ARV portfolio comprising of TLD (Tenofovir / Lamivudine / Dolutegravir 300 / 300 / 50mg), DTG (Dolutegravir 50mg) and ET (Emtricitabine / Tenofovir 200 / 300mg).
TLE 400 is the alternative first line regimen for treatment of HIV/AIDS as per the WHO guidelines issued in July 2019.
Shares of Laurus Labs Ltd was last trading in BSE at Rs.326.5 as compared to the previous close of Rs. 329.3. The total number of shares traded during the day was 461 in over 81 trades.
The stock hit an intraday high of Rs. 327.3 and intraday low of 324. The net turnover during the day was Rs. 150289.